AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up

By Reuters News

Sept 28 (Reuters) - Summit Therapeutics SMMT.O said on Monday that British drugmaker AstraZeneca AZN.L would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.

Summit's shares rose over 15% in extended trading following the announcement.


Here are some details:

  • AstraZeneca will buy preferred shares in Summit at an equivalent price of $18.36 per common share, representing an 18.6% premium to Summit's Monday closing price of $15.48.

  • The investment marks a major vote of confidence in ivonescimab, a next-generation cancer treatment licensed by Summit from China's Akeso 9926.HK.

  • Ivonescimab works by simultaneously blocking PD-1, which helps cancer evade the immune system, and VEGF, which tumors use to grow blood vessels, helping the immune system better find and attack cancer cells.

  • As part of the partnership, the two companies will also launch clinical trials combining ivonescimab with AstraZeneca's cancer treatments.

  • They have also signed a preliminary agreement to explore testing ivonescimab with several other AstraZeneca medicines, including its antibody-drug conjugates, a class of treatments that deliver cancer-killing drugs directly to tumor cells.

  • The transaction is expected to close by the end of the week.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.